Sjögren Syndrome in Primary Care: A Quiz

Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.

A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.

We reviewed new psoriatic arthritis approvals as well as data readouts from head-to-head trials and milestone data in IgG4-related disease.